609,112 Shares in MiMedx Group, Inc $MDXG Acquired by OP Asset Management Ltd

OP Asset Management Ltd bought a new position in MiMedx Group, Inc (NASDAQ:MDXG) in the first quarter, Holdings Channel.com reports. The fund bought 609,112 shares of the company’s stock, valued at approximately $2,406,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in MDXG. Kemnay Advisory Services Inc. bought a new stake in shares of MiMedx Group in the 4th quarter worth $48,000. Headlands Technologies LLC bought a new position in MiMedx Group during the second quarter valued at about $72,000. Jain Global LLC acquired a new position in MiMedx Group during the fourth quarter worth about $73,000. Virtu Financial LLC acquired a new position in MiMedx Group during the fourth quarter worth about $78,000. Finally, Osaic Holdings Inc. raised its position in MiMedx Group by 57.2% in the second quarter. Osaic Holdings Inc. now owns 12,943 shares of the company’s stock worth $79,000 after acquiring an additional 4,708 shares in the last quarter. 79.15% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the stock. Craig Hallum cut their price target on shares of MiMedx Group from $10.00 to $7.00 and set a “buy” rating for the company in a report on Friday, April 17th. Wall Street Zen downgraded shares of MiMedx Group from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. Weiss Ratings lowered shares of MiMedx Group from a “sell (d+)” rating to a “sell (d)” rating in a research note on Monday, May 18th. Finally, Citizens Jmp cut their target price on shares of MiMedx Group from $7.00 to $6.00 and set a “market outperform” rating for the company in a research note on Thursday, April 30th. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, MiMedx Group has a consensus rating of “Moderate Buy” and a consensus price target of $8.50.

MiMedx Group Stock Performance

Shares of MiMedx Group stock opened at $3.93 on Friday. MiMedx Group, Inc has a 12 month low of $3.03 and a 12 month high of $7.99. The company has a quick ratio of 4.81, a current ratio of 5.39 and a debt-to-equity ratio of 0.07. The stock has a market cap of $585.37 million, a PE ratio of 19.65 and a beta of 1.48. The business has a fifty day simple moving average of $3.59 and a 200-day simple moving average of $4.71.

MiMedx Group (NASDAQ:MDXG) last posted its quarterly earnings results on Wednesday, April 29th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.02. The firm had revenue of $58.99 million for the quarter, compared to analyst estimates of $65.80 million. MiMedx Group had a return on equity of 21.03% and a net margin of 7.88%. On average, sell-side analysts anticipate that MiMedx Group, Inc will post -0.01 EPS for the current fiscal year.

MiMedx Group Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.